At numerous events throughout the year, TTC’s Invention Development and Marketing Unit (IDMU) proactively engages companies...

Advances involving NCI tumor-infiltrating lymphocytes (TIL) immunotherapies were recently featured in Nature Biotechnology:...

Recent NCI collaborations with industry are highlighted in a May 2019 feature article by BioBuzz entitled: "Three Examples...

Three new cancer therapies recently approved by the Federal Drug Administration (FDA) – avelumab (BAVENCIO®),...